CA3009154A1 - Tlr inhibitory oligonucleotides and their use - Google Patents

Tlr inhibitory oligonucleotides and their use Download PDF

Info

Publication number
CA3009154A1
CA3009154A1 CA3009154A CA3009154A CA3009154A1 CA 3009154 A1 CA3009154 A1 CA 3009154A1 CA 3009154 A CA3009154 A CA 3009154A CA 3009154 A CA3009154 A CA 3009154A CA 3009154 A1 CA3009154 A1 CA 3009154A1
Authority
CA
Canada
Prior art keywords
seq
oligonucleotide
disease
mediated
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3009154A
Other languages
English (en)
French (fr)
Inventor
Eiji ESASHI
Koji Ishida
Takumi Hosozawa
Megumi Okuyama
Ayumi KOTAKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of CA3009154A1 publication Critical patent/CA3009154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3009154A 2015-12-25 2016-12-22 Tlr inhibitory oligonucleotides and their use Abandoned CA3009154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-255008 2015-12-25
JP2015255008 2015-12-25
PCT/JP2016/088418 WO2017111045A1 (en) 2015-12-25 2016-12-22 Tlr inhibitory oligonucleotides and their use

Publications (1)

Publication Number Publication Date
CA3009154A1 true CA3009154A1 (en) 2017-06-29

Family

ID=59090457

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3009154A Abandoned CA3009154A1 (en) 2015-12-25 2016-12-22 Tlr inhibitory oligonucleotides and their use

Country Status (9)

Country Link
US (1) US10806749B2 (enExample)
EP (1) EP3394263B1 (enExample)
JP (1) JP7079495B2 (enExample)
KR (1) KR20180089531A (enExample)
CN (1) CN108431228A (enExample)
AU (1) AU2016375543A1 (enExample)
CA (1) CA3009154A1 (enExample)
IL (1) IL260193A (enExample)
WO (1) WO2017111045A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
CN109266732A (zh) * 2018-09-13 2019-01-25 中山大学附属第医院 TLR7和TLR8作为IgA肾病预防治疗靶点的应用及TLR7的抑制剂及其应用
CN114569722B (zh) * 2022-03-07 2022-11-22 广州市妇女儿童医疗中心 抑制血小板焦亡的试剂在制备预防和/或治疗脓毒症的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011520A (enExample) 1973-05-31 1975-02-06
AU2003275776B2 (en) * 2002-11-08 2009-06-18 Jingang Medicine (Australia) Pty Ltd A method for optimising gene expression using synonymous codon optimisation
IL161579A0 (en) * 2004-04-22 2004-09-27 Mor Research Applic Ltd ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
US8030289B2 (en) 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
PL2154144T3 (pl) 2008-08-06 2015-04-30 Changchun Huapu Biotechnology Co Ltd Oligonukleotydy i ich zastosowanie
CN101696434A (zh) * 2009-10-27 2010-04-21 中国科学院过程工程研究所 β-聚苹果酸发酵新工艺
WO2014082254A1 (en) * 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof
US20170240896A1 (en) * 2014-02-07 2017-08-24 Sbi Biotech, Co., Ltd. Inhibitory Oligonucleotides for Treating Tumors

Also Published As

Publication number Publication date
KR20180089531A (ko) 2018-08-08
IL260193A (en) 2018-07-31
JP2019500873A (ja) 2019-01-17
AU2016375543A1 (en) 2018-06-28
EP3394263A1 (en) 2018-10-31
EP3394263A4 (en) 2019-08-21
CN108431228A (zh) 2018-08-21
JP7079495B2 (ja) 2022-06-02
US20190008888A1 (en) 2019-01-10
US10806749B2 (en) 2020-10-20
EP3394263B1 (en) 2025-02-26
WO2017111045A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US10190122B2 (en) Inhibitory oligonucleotide and use thereof
EP3394263B1 (en) Tlr inhibitory oligonucleotides and their use
US8470342B2 (en) Methods of altering an immune response induced by CpG oligodeoxynucleotides
US8940310B2 (en) Methods of treatment using TLR7 and/or TLR9 inhibitors
WO2011159328A1 (en) Methods of treatment using tlr7 and/or tlr9 inhibitors
US8030289B2 (en) Oligonucleotide and use thereof
WO2014052931A1 (en) Human toll-like receptor inhibitors and methods of use thereof
EP2154144B1 (en) Oligonucleotides and use thereof
WO2015120322A1 (en) Inhibitory oligonucleotides for treating tumors
JP6307190B2 (ja) 阻害性オリゴヌクレオチド及びその使用
CA2638176C (en) Oligonucleotide and use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220622